Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31


Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.

Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, Brown K.

Cancer Res. 2010 Oct 1;70(19):7392-9. doi: 10.1158/0008-5472.CAN-10-2027. Epub 2010 Sep 14.


Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites.

Hoshino J, Park EJ, Kondratyuk TP, Marler L, Pezzuto JM, van Breemen RB, Mo S, Li Y, Cushman M.

J Med Chem. 2010 Jul 8;53(13):5033-43. doi: 10.1021/jm100274c.


Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies.

Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Roddam AW.

Lancet Oncol. 2010 Jun;11(6):530-42. doi: 10.1016/S1470-2045(10)70095-4. Epub 2010 May 14.


Pleiotropic mechanisms facilitated by resveratrol and its metabolites.

Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD, Mesecar AD.

Biochem J. 2010 Jul 15;429(2):273-82. doi: 10.1042/BJ20091857.


Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects.

Nunes T, Almeida L, Rocha JF, Falcão A, Fernandes-Lopes C, Loureiro AI, Wright L, Vaz-da-Silva M, Soares-da-Silva P.

J Clin Pharmacol. 2009 Dec;49(12):1477-82. doi: 10.1177/0091270009339191. Epub 2009 Oct 1. No abstract available.


Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.

Almeida L, Vaz-da-Silva M, Falcão A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, Soares-da-Silva P.

Mol Nutr Food Res. 2009 May;53 Suppl 1:S7-15. doi: 10.1002/mnfr.200800177.


Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span.

Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R.

Cell Metab. 2008 Aug;8(2):157-68. doi: 10.1016/j.cmet.2008.06.011. Epub 2008 Jul 3.


Resveratrol from red grapes - pedestrian polyphenol or useful anticancer agent?

Gescher AJ.

Planta Med. 2008 Oct;74(13):1651-5. doi: 10.1055/s-2008-1074516. Epub 2008 Apr 29.


Understanding pathways of calorie restriction: a way to prevent cancer?

Grifantini K.

J Natl Cancer Inst. 2008 May 7;100(9):619-21. doi: 10.1093/jnci/djn142. Epub 2008 Apr 29. No abstract available.


Resveratrol suppresses prostate cancer progression in transgenic mice.

Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, Lamartiniere CA.

Carcinogenesis. 2007 Sep;28(9):1946-53. Epub 2007 Aug 3.


Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.

Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE.

Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1246-52.


Resveratrol: a review of preclinical studies for human cancer prevention.

Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL.

Toxicol Appl Pharmacol. 2007 Nov 1;224(3):274-83. Epub 2007 Jan 3. Review.


Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography.

Boocock DJ, Patel KR, Faust GE, Normolle DP, Marczylo TH, Crowell JA, Brenner DE, Booth TD, Gescher A, Steward WP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):182-7. Epub 2006 Nov 9.


Resveratrol improves health and survival of mice on a high-calorie diet.

Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA.

Nature. 2006 Nov 16;444(7117):337-42. Epub 2006 Nov 1.


Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats.

J G, Cq W, Hh F, Hy D, Xl X, Ym X, By W, Dj H.

J Cardiovasc Pharmacol. 2006 May;47(5):711-21.


Therapeutic potential of resveratrol: the in vivo evidence.

Baur JA, Sinclair DA.

Nat Rev Drug Discov. 2006 Jun;5(6):493-506. Epub 2006 May 26. Review.


Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps.

Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, Rosen CJ.

Gastroenterology. 2005 Aug;129(2):464-75.


Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers.

Lee HY, Chang YS, Han JY, Liu DD, Lee JJ, Lotan R, Spitz MR, Hong WK.

J Clin Oncol. 2005 Jul 1;23(19):4439-49.


High absorption but very low bioavailability of oral resveratrol in humans.

Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK.

Drug Metab Dispos. 2004 Dec;32(12):1377-82. Epub 2004 Aug 27.


Insulin-like growth factor-I and cancer risk.

Ibrahim YH, Yee D.

Growth Horm IGF Res. 2004 Aug;14(4):261-9. Review.


Supplemental Content

Support Center